|
IN APPRECIATION OF DR. RAMESH SHIVDASANI
Founding BOSA Chair
The NETRF Board of Scientific Advisors (BOSA), Board of Directors, and staff wish to thank Dr. Ramesh Shivdasani for his incredible leadership as BOSA Co-Chair from the panel’s founding in 2007 to 2016.His leadership has been instrumental in the development of NETRF’s now proven grant making process and the expansion of neuroendocrine tumor research world-wide, through NETRF funding.
Under his leadership, NETRF has emerged as a prestigious and impactful funder of neuroendocrine tumor research attracting research proposals from top scientists and funding projects that have made significant advances in our understanding of neuroendocrine tumors.The Foundation is grateful for his dedication through his many years of service.
“Dr. Shivdasani's extraordinary intelligence, judgement, scientific taste, and reputation within the scientific community have been invaluable to the Foundation, and he now leaves our Board of Scientific Advisors in excellent hands” comments Stephen Blackwood, member of the NETRF Board of Directors.
Dr. Joe Li, Vice Chair of the Board of Directors, recognizes Dr. Shivdasani for his service and compassion. “Ramesh is remarkably adept at explaining complicated science in a way that anyone could understand.But perhaps his greatest contribution is his kindness in supporting us as patients, family and friends who are living with this disease.” READ MORE
| |
|
JOSH MAILMAN JOINS NETRF BOARD OF DIRECTORS
Internationally Recognized NET Patient Advocate
The NETRF Board of Directors is pleased to announce that Josh Mailman has joined the Board. Josh is an internationally-recognized advocate for neuroendocrine tumor patients as well as an advocate for integrative oncology and nuclear medicine and molecular imaging.He is the inaugural Chairman of the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) Patient Advocacy Advisory Board, a member of The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) Board and President of NorCal CarciNET Community, one of the largest NET patient groups in the United States.In addition, he has been a member of the National Cancer Institute’s Task Force on Neuroendocrine Tumors for more than three years.
“Josh is one of the most committed, effective, and respected leaders in the NET community," said Ron Hollander, NETRF Executive Director. “We are looking forward to having his perspective and his passion on our Board to help us accelerate our research for better treatments and cures for neuroendocrine cancers.” READ MORE
| |
|
NYC PATIENT CONFERENCE TO FEATURE INTERNATIONAL PERSPECTIVES
Register by Sunday, October 30
NETRF’s next patient educational conference, to be held on November 10, 2016, will feature unique international perspectives on neuroendocrine tumor research and treatment. The program happens on World NET Cancer Awareness Day, a day set aside around the world to increase awareness of neuroendocrine cancer and honor the patients and families fighting the disease.
The program brings together an outstanding group of experts from the NYC area and as far away as Germany and Australia to discuss the latest discoveries and clinical care.The agenda includes summaries of recent national and international NET meetings, as well as the results of a global NET patient experience survey.Presentations will include clinical trials, immunotherapy, PRRT, surgery options, symptom management, and integrative psychosocial health. READ MORE
| |
|
PETERSEN INVESTIGATOR DR. GIGI LOZANO
Working to Unlock the Mysteries of Pancreatic Neuroendocrine Tumors
Dr. Guillermina Lozano, Ph.D. of MD Anderson Cancer Center has worked tirelessly to understand how pancreatic neuroendocrine tumors develop so that we might use that knowledge to discover new therapies. NETRF has recognized Dr. Lozano as a Petersen Investigator and awarded her a 2016 grant, thanks to generous support from the Margie and Robert E. Petersen Foundation.
The goal of Dr. Lozano’s current research project is to identify the cellular changes that occur when DAXX and ATRX gene mutations are present and how these changes lead to the development of neuroendocrine tumors. Dr. Lozano’s team has extensive experience in generating mouse models to study the effects of specific mutations on tumor development. Previous NETRF-funded researchers discovered mutations in the DAXX and ATRX genes in tumors from patients with non-functioning pancreatic neuroendocrine tumors. READ MORE
| |
|  | Pictured from left, Dr. Pam Kunz, Dr.Christopher Heaphy, Ron Hollander, and Dr James Howe |
|
NETRF/NANETS NAMES FIRST BTSI RESEARCHER
Supporting Research Through Collaboration
Dr. Christopher Heaphy of Johns Hopkins University has been selected as the first Basic Translational Science Investigator, through a collaboration between NETRF and The North American Neuroendocrine Tumor Society (NANETS). The two-year award to Dr. Heaphy was announced at NANETS’ annual meeting in Wyoming in September. READ MORE
| |
|  |
Pictured from left, Neal Yaffe, Ilana Herzberg, and Arielle Herzberg |
|  |
Pictured from left, Neal Yaffe, Ilana Herzberg, Arielle Herzberg, Shari Koll, and Lisa Herzberg |
|
SPECIAL THANKS FOR CHICAGO MARATHON PERSONAL BESTS
Honoring Her Father by Supporting Research
Ilana Herzberg accomplished two goals in October—running the Chicago Marathon in memory of her father and posting a personal best time. She increased her annual fundraising total for NETRF and finished the race in 3 hours, 39 minutes, a personal best. We thank Ilana for her energy and commitment to helping NETRF. READ MORE
| |
| We are pleased to announce that this eUpdate
is sponsored by Novartis Pharmaceutical Corporation.
| |
|
|
|
|
